Action TCRR TCR2 THERAPEUTICS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues TCR2 Therapeutics Inc.

Actions

TCRR

US87808K1060

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from NASDAQ Composite Index
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P Global BMI Index
TCR2 Therapeutics Inc.(NasdaqGS:TCRR) dropped from S&P TMI Index
Adaptimmune Therapeutics plc completed the acquisition of TCR2 Therapeutics Inc. from a group of shareholders.
TCR2 THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
TCR2 Therapeutics : Merger Agreement - Form 8-K
TCR-2 THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
TCR2 Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
TCR2 THERAPEUTICS INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TCR² Therapeutics Inc. - TCRR
TCR-2 THERAPEUTICS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
North American Morning Briefing : Stock Futures -2-
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action TCRR
  4. Actualités TCR2 Therapeutics Inc.
  5. Autres langues